Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Standard induction therapy with lenalidomide, bortezomib, and dexamethasone did not overcome inferior outcomes in patients ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics made a pivotal discovery in the field ...

Bone-marrow-derived multipotent progenitor stromal ... cues encountered following in vivo administration. Indeed, the microenvironment dictates the final effect of MSCs on target cells, as ...

Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.Continued ...

Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a ...

In people with AML, bone marrow blood vessels increase E-selectin expression ... why don't we utilize this cue to home the NK cells better to this particular subsite of the microenvironment where the ...

More information: Tongling Huang et al, Targeting adipocyte ESRRA promotes osteogenesis and vascular formation in adipocyte-rich bone marrow, Nature Communications (2024). DOI: 10.1038/s41467-024 ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics made a pivotal discovery in the field ...